High Herceptin Costs Leave Patients Untreated, Say UK Doctors
Posted on: Friday, 24 November 2006, 09:00 CST
The high cost of cancer drug Herceptin to the UK's National Health Service is leaving some patients without treatment, according to a group of doctors.
In the British Medical Journal, the doctors say that new guidance from the National Institute for Health and Clinical Excellence (NICE) recommends trastuzumab (marketed as Herceptin by Genentech) in early breast cancer, but it provides no extra funding and does not suggest what cuts should be made to release this extra money. This leaves medical staff with difficult decisions to make, they add.
Doctors at the Norfolk and Norwich University Hospital NHS Trust and the University of East Anglia calculated that they will have to find GBP1.9 million each year to make Herceptin available to the patients who may be eligible. This becomes GBP2.3 million if the costs of testing and monitoring patients are added.
However, the doctors calculated that hospitals can only afford Herceptin if they did not treat 355 patients receiving adjuvant treatment (16 of whom would be cured) or 208 patients receiving palliative chemotherapy, and if they found GBP500,000 from another source.
"These untreated patients will be people we know," say the authors. "We will be the ones to tell them they are not getting treatment that has been proved to be effective and which costs relatively little, because it is not the treatment of the moment."
They believe that NICE should be given responsibility to decide what should be cut to fund newly recommended technologies or the ability to allocate extra funds for implementation, or both.
Source: Datamonitor
Related Articles
- Repligen Announces Completion of Patient Treatment in Phase 3 Clinical Trial of RG1068 in MRI Imaging of the Pancreas
- Oculus Completes Patient Treatment in Phase II Diabetic Foot Ulcer Trial
- Oculus Innovative Sciences Completes Patient Treatment and Follow-Up in Its Phase II Clinical Trial in Mildly Infected Diabetic Foot Ulcers
- Patient Treatment for Bipolar Disorder Varies Depending on Doctor Specialty; Well Designed Clinical Trials May Be The Answer
- USNS Comfort Conducts 55,465 Patient Treatments in First Month
- Viventia Initiates Patient Treatment in Bladder Cancer Trial
- Consumer Reports Survey: Patients and Doctors Disagree on Some Essential Issues
- Work Starts on ASH's List of Repairs: Recent Analysis Showed Breakdowns in Patient Treatment
- Patients and Doctors Join Governor Schwarzenegger and U.S. Senator Dianne Feinstein at UCLA Today to Call for Passage of Federal Legislation That Bans Cloning but Supports Stem Cell Research
- ImClone Systems Commences Patient Treatment in U.S. Phase I Clinical Trial Of IMC-1121B
 |
 |
User Comments (0)
RSS Feeds